Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, et al
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Summary: This Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of co-administering once-weekly subcutaneous cagrilintide (at various doses) with semaglutide 2.4 mg in participants for weight management
In addition to tissue regeneration, further research has also identified the body protection compound could improve cognitive function, stimulate the production of new blood vessels and promote gut health
Adrenergic stimulation can increase myocardial oxygen consumption, lead to the downregulation of -adrenergic receptors, and reverse adrenergic G protein coupling, resulting in impaired myocardial contractility and septic cardiomyopathy, particularly during prolonged administration [31, 32]